Shots:
- The US FDA has approved Pfizer‘s Ibrance (palbociclib) + trastuzumab ± pertuzumab, & endocrine therapy for the maintenance treatment of adults with HR+, HER2+ locally advanced or metastatic breast cancer following induction treatment
- Approval was based on the AFT-sponsored P-III (PATINA) trial, where pts receiving a median of 6 cycles of induction treatment were randomized to either Ibrance combination (n=261) or anti-HER2 therapy with endocrine therapy (n=257)
- Trial showed improved PFS, with a 24% reduction in the risk of progression or death following induction treatment, while the OS data remain immature. Results were published by AFT in The NEJM
Ref: Businesswire | Image: Pfizer | Press Release
Related News: Pfizer Receives the US FDA Approval for Hympavzi to Treat Hemophilia A or B in Two Populations
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
